A Mobile App-Based, Prospective, Observational Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) patients and their caregivers.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Diagnosis of IgAN, regardless of symptom or treatment history
• Adult aged 18 or older; adult caregiver to an adult patient aged 18 or older; or adult caregiver to a pediatric patient under 18 years of age
• US-based with a proficient understanding of and ability to read the English language
Locations
United States
Massachusetts
Novartis Investigational site
RECRUITING
Boston
Contact Information
Primary
Novartis Pharmaceuticals
novartis.email@novartis.com
+41613241111
Backup
Novartis Pharmaceuticals
Time Frame
Start Date: 2025-03-04
Estimated Completion Date: 2025-06-30
Participants
Target number of participants: 300
Treatments
Immunoglobulin A nephropathy (IgAN)-Iptacopan
IgAN patients taking iptacopan and their caregivers
IgAN-atrasentan
IgAN patients taking atrasentan and their caregivers
IgAN-other treatment
IgAN patients taking other specific treatment and their caregivers
IgAN-no treatment
IgAN patients taking none treatment and their caregivers
Related Therapeutic Areas
Sponsors
Leads: Novartis Pharmaceuticals